News

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, is proud to announce the designation of Katie Brennan, MD, PhD, at Queen Elizabeth University Hospital (QEUH) in Glasgow, Scotland, as a CMTA Center of Excellence, ...

CMTA is proud to share that research led by CMTA Strategy to Accelerate Research (CMTA-STAR) Scientific Advisory Board member Maurizio D’Antonio, PhD, has been published in the leading scientific neurology journal, Brain. With CMTA funding support, this study highlights the ...

With CMTA’s support, researchers at San Raffaele Scientific Institute in Milan, Italy, led by Alessandra Bolino, PhD, are making significant progress in developing an AAV9-based genetic therapy for CMT4B1. This $380,000 CMTA Strategy To Accelerate Research (CMTA-STAR) investment is part ...

The Charcot-Marie-Tooth Association (CMTA) is investing $300,000 in a groundbreaking gene editing research project at Gladstone Institutes to develop a CRISPR-based therapy for CMT2A. This CMTA Strategy To Accelerate Research (CMTA-STAR) initiative aims to create a single solution for multiple ...

CMTA Strategy To Accelerate Research (CMTA-STAR) Advisory Board member and clinic director of the CMTA Center of Excellence at the C. Besta Neurological Institute in Milan, Italy, Davide Pareyson, MD, and colleagues review the latest advancements in Charcot-Marie-Tooth disease (CMT). ...